Professor Ji-Liang Li
Profiles

Professor Ji-Liang Li

Professor/Chair in Cancer Immunology

Biomedical Research - Institute of Translational & Stratified Medicine (Plymouth University Peninsula Schools of Medicine and De

Role

Professor & Chair of Cancer Immunology
Plymouth University Peninsula School of Medicine

Qualifications

  • PhD, Molecular Medicine, London School of Tropical Medicine & Hygiene, University of London, UK (1997)
  • MMed, Medicine, Sun Yat-Sen University College of Medicine, Guangzhou, China
  • MD, Medicine, Suzhou Medical College, Suzhou, China
Previous positions
  • 2007–2015:   Deputy Lab Head/Tenured Scientist, Weatherall Institute of Molecular Medicine, University of Oxford, UK;
  • 2002–2007:   Tenured Staff Scientist/Deputy Lab Head, Cancer Research UK (CRUK), UK;
  • 1999–2002:   Research Fellow, Imperial Cancer Research Fund (ICRF), UK;
  • 1996–1999:   Postdoc Research Associate, Department of Biochemistry, University of Oxford, UK.

Professional membership

  • American Association for Cancer Research

Roles on external bodies

Invited Peer Review for Research Grants/Fellowships
  • Breast Cancer Campaign
  • British Heart Foundation
Invited Peer Review for >40 Professional Journals    
  • Gut
  • Blood
  • Cancer Research
  • Clinical Cancer Research                      
  • Oncogene
  • Journal of Pathology 
Editorial/Scientific Board Members    

Teaching interests

Cancer Biology and Cancer Immunology

Research interests

My research interest focuses on tumour microenvironment and translational cancer medicine. By employing a variety of approaches including molecular biology, cell biology, immunology, proteomics, next-generation sequencing, bioinformatics, animal models, human tumour samples and relevant clinical data, my research is dedicated to delineate mechanisms on how key molecules (such as microRNAs, lncRNAs, and RN181 E3 ligase), signalling pathways (such as Notch signalling), tumour cells, and tumour stromal cells (such as endothelial cells, infiltrating lymphocytes, tumour-associated macrophages, and tumour-associated fibroblasts) in tumour microenvironment regulate tumour growth and metastasis and tumour response to therapeutic interventions (in particular, cross-interactions among radiotherapy, chemotherapy, targeted therapy and immunotherapy). My aims are (1) to dissect mechanisms of tumour migration, invasion and metastasis, (2) to develop novel therapeutic targets or biomarkers, and (3) to improve therapeutic efficacy by optimal combinations of radiotherapy, chemotherapy, targeted therapy, or immunotherapy. Primary cancer types I am currently working on include, but not limit to, brain tumour (eg, gliomas), gastrointestinal tumour (eg, gastric, colorectal and hepatic cancer), and head & neck cancer (eg, nasopharyngeal carcinoma). 

Tumour Microenvironment and Translational Cancer Medicine 

  • Cancer Immunology
  • Tumour associated macrophage
  • Tumour invasion and metastasis
  • Hypoxia and angiogenesis pathways 
  • Notch signalling in cancer biology 
  • Cancer-associated lncRNAs and MicroRNAs
  • Tumour resistance to therapeutic treatments
  • Optimal combination therapy 
  • Preclinical mouse tumour models

Representative Publications

  1. Cai L, Ye Y, Jiang Q, Chen Y, Lyu X, et al. (2015): Epstein-Barr virus-encoded microRNA BART1 induces tumour metastasis by regulating PTEN-dependent pathways in nasopharyngeal carcinoma. Nature Commun. Jul 2; 6:7353. doi:10.1038/ncomms8353.
  2. Masiero M, Simões FC, Han HD, Snell C, Peterkin T, et al. (2013): A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell. Aug 12; 24(2):229-41. 
  3. Li JL, Sainson RC, Oon CE, Turley H, Leek R, et al. (2012): DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res. Sep 15; 71(18):6073-83. 
  4. Wang S, Huang X, Li Y, Lao H, Zhang Y, et al. (2011): RN181 suppresses hepatocellular carcinoma growth by inhibition of the ERK/MAPK pathway. Hepatology. Jun; 53(6):1932-42.
Graduate Student, Clinical Fellow, Visiting Fellow and Postdoctoral Positions: Enquiries with CV welcome at any time.

Currently, both core-funded Senior Research Fellow in Cancer Biology (Grade 8) and PhD studentship are available: (http://www.nature.com/naturejobs/science/jobs/572531-senior-research-fellow-in-cancer-biology-immunology) and (http://www.nature.com/naturejobs/science/jobs/571871-5-fully-funded-phd-positions-in-cancer-brain-tumour-research).

In addition, several self-funded PhD studentships and/or visiting fellows will be expected in 2016/2017.

Selected Publications (10 key publications are highlighted by linking to the journal website)

  1. Oon, C.E., Bridges, E., Sheldon, H., Sainson, R.C.A., Jubb, A.,Turley, H., Leek, R., Buffa, F., Harris, A.L. and *Li, J.L. (2017): Role of Delta-like 4 in Jagged1-induced tumour angiogenesis and tumour growth. Oncotarget, Apr 8; doi: 10.18632/oncotarget.16969 (*corresponding author).
  2. da Motta, L.L., Ledaki, I., Purshouse, K., Haider, S., De Bastiani, M.A., Baban, D., Morotti, M., Steers, G., Wigfield, S., Bridges, E., Li, J.L., Knapp, S., Ebner, D., Klamt, F., Harris, A.L., McIntyre, A. (2017): The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer. Oncogene, Jan 5; 36(1):122-132. doi: 10.1038/onc.2016.184.
  3. McIntyre, A., Hulikova, A., Ledaki, I., Snell, C., Singleton, D., Steers, G., Seden, P., Jones, D., Bridges, E., Wigfield, S., Li, J.L., Russell, A., Swietach, P. and Harris, A.L. (2016): Disrupting hypoxia-induced bicarbonate transport acidifies tumor cells and suppresses tumor growth. Cancer Research, Jul 1; 76(13):3744-3755. doi: 10.1158/0008-5472.CAN-15-1862.
  4. Fan, S.J., Snell, C., Turley, H., Li, J.L,, McCormick, R., Perera, S.M., Heublein, S., Kazi, S., Azad, A., Wilson, C., Harris, A.L., Goberdhan, D.C. (2016): PAT4 levels control amino-acid sensitivity of rapamycin-resistant mTORC1 from the Golgi and affect clinical outcome in colorectal cancer. Oncogene, Jun 9; 35(23):3004-3015. doi: 10.1038/onc.2015.363.
  5. He, P., Wang, S., Zhang, X., Gao, Y., Niu, W., Dong, N., Shi, X., Geng, Y., Ma, Q., Li, M., Jiang, B. and *Li, J.L. (2016): Tspan5 is an independent favourable prognostic factor and suppresses tumour growth in gastric cancer. Oncotarget, May 20; 7(26): 40160-40173. doi: 10.18632/oncotarget.9514. (*corresponding author)
  6. Chen, Y., Wang, S., Liu, T., Wu, Y., *Li, J.L., Li, M. (2016): WAP four-disulfide core domain protein 2 gene (WFDC2) is a target of estrogen in ovarian cancer cells. J Ovarian Res., Feb 29; 9:10. doi: 10.1186/s13048-015-0210-y. (*corresponding author)
  7. He, B., Xiao, Y.F., Tang, B., Wu, Y.Y., Hu, C.J., Xie, R., Yang, X., Yu, S.T., Dong, H., Zhao, X.Y, *Li, J.L. and Yang, S.M. (2016): hTERT mediates gastric cancer metastasis partially through the indirect targeting of ITGB1 by microRNA-29a. Scientific Reports, Feb 23; 6:21955. doi:10.1038/srep21955. (*corresponding author).
  8. Yang, J., Tahan, A.A., Jones, D.T., Buffa, F.M., Bridges, E., Interiano, R.B., Qu, C., Vogt, N., Li, J.L. et al. (2015): Estrogen receptor-α directly regulates the hypoxia-inducible factor 1 pathway associated with antiestrogen response in breast cancer. Proc Natl Acad Sci U S A., Dec 8; 112(49): 15172-15177. doi: 10.1073/pnas.1422015112. 
  9. Ramcharan, R., Aleksic, T., Gao, S., Kamdoum, W.P., Tanner, J., Bridges, E., Asher, R., Watson, A.J., Margison, G.P., Woodcock, M., Repapi, E., Li, J.L., Middleton, M.R. and Macaulay, V.M. (2015): IGF-1R inhibition induces schedule-dependent sensitization of melanoma to temozolomide. Oncotarget, Nov 24; 6(37): 39877-39890. doi: 10.18632/oncotarget.5631.
  10. Ledaki, I., McIntyre, A., Wigfield, S., Buffa, F., McGowan, S., Baban, D., Li, J.L. and Harris, A.L. (2015): Carbonic anhydrase IX induction defines a heterogeneous cancer cell response to hypoxia and mediates stem cell-like properties and sensitivity to HDAC inhibition. Oncotarget, Aug 14; 6(23):19413-19427. DOI: 10.18632/oncotarget.4989
  11. Cai, L., Ye, Y., Jiang, Q., Lyu, X., Chen,Y., Li, J., Wang, S., Liu, T., Yao, K., *Li, J.L. and Li, X. (2015): Epstein-Barr virus-encoded microRNA BART1 induces tumour metastasis by regulating PTEN-dependent pathways in nasopharyngeal carcinoma. Nature Commun., July 2; 6:7353. doi:10.1038/ncomms8353. (*corresponding and co-senior author).  
  12. Leung, W.Y., Roxanis, J., Sheldon, H., Buffa, F.M., Li, J.L., Harris, A.L. and Kong, A. (2015): Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signaling in HER2 amplified breast cancer. Oncotarget, Mar 20; 6(8): 5678-5694. DOI: 10.18632/oncotarget.3296
  13. Zhao W., Yin, J., Yang, Z., Xie, J., Zhang, Y., Xu, W. and *Li, J.L. (2015): Meta-analysis of androgen insensitivity in preoperative hormone therapy in hypospadias. Urology, May; 85(5): 1166-1172. doi: 10.1016/j.urology.2015.01.035. (*corresponding author)
  14. Singleton, D., Rouhi, P., Haider, S., Zois, C.E., Li, J.L., Kessler, B.M., Cao, Y. and Harris, A.L. (2015): Hypoxic regulation of RIOK3 is a major mechanism for cancer cell invasion and metastasis. Oncogene, Sep 3; 34(36): 4713-4722. doi: 10.1038/onc.2014.396. 
  15. Bensaad, K., Favaro, E., Lewis, C.A., Lord, S., Collins, J.M., Pinnick, K., Buffa, F., Li, J.L. et al. (2014): Fatty acid uptake and lipid storage induced by HIF-1a contribute to cell survival in hypoxia-reoxygenation. Cell Report, Oct 9; 9(1): 349-365. doi: 10.1016/j.celrep.2014.08.056.
  16. Feldinger, K., Generali, D., Kramer-Marek, G., Gijsen, M., Ng, T.B., Wong, J.H., Strina, C., Cappelletti, M., Andreis, D., Li, J.L. et al. (2014): ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer. Oncotarget, Aug 30; 5(16):6633-6646. DOI: 10.18632/oncotarget.1955.
  17. Lyu, X., Fang, W., Zheng, H., Cai, L., Ye, Y., Zhang, L., Li, J., Peng, H., Cho, W.C, Wang, E., Marincola, F.M., Yao, K., Cai, H., *Li, J.L. and Li, X. (2014): TGFβR2 is a major target of microRNA-93 in nasopharyngeal carcinoma aggressiveness. Molecular Cancer, Mar 8; 13(1): 51. doi: 10.1186/1476-4598-13-51.  (*corresponding author).
  18. Mohd Nafi, S.N., Generali, D., Kramer-Marek, G., Gijsen, M., Cappelletti, M., Andreis, D., Haider, S., Li, J.L. et al. (2014): Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer. Oncotarget, Aug 15; 5(15): 5934-5949. DOI: 10.18632/oncotarget.1904.
  19. Canonici, A.,Gijsen, M., Mullooly, M., Bennett, R., Bouguern, N., Pedersen, K., O’Brien, N.A., Roxanis, I., Li, J.L. et al. (2013): Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget, Oct; 4(10):1592-605. DOI: 10.18632/oncotarget.1148.
  20. Masiero, M., Simões, F.C., Han, H.D., Snell, C., Peterkin, T., Bridges, E., Mangala, L.S., Wu, S.Y., Pradeep, S., Li, D., Han, C., Dalton, H., Lopez-Berestein, G., Tuynman, J.B., Mortensen, N., Li, J.L. et al. (2013): A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell, Aug 12; 24(2): 229-241. doi: 10.1016/j.ccr.2013.06.004.
  21. Kumar,K., Wigfield, S., Gee, H.E., Devlin, C.M., Singleton, D., Li, J.L., Buffa, F., Huffman, M., Sinn, A.L., Silver, J., Turley, H., Leek, R., Harris, A.L. and Ivan, M. (2013): Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhance its antitumor effects in mouse xenografts. Journal of Molecular Medicine, Jun; 91(6):749-758. doi: 10.1007/s00109-013-0996-2. 
  22. Whiteman, P., Hernandez de Madrid, B., Taylor, P., Li, D., Heslop, R., Vichitcheep, N., Tan, J.Z., Shimizu, H., Callaghan, J., Masiero, M., Li, J.L. et al. (2013): Molecular basis for Jagged-1/Serrate recognition by Notch. The Journal of Biological Chemistry, Mar 8; 288(10):7305-7312. doi: 10.1074/jbc.M112.428854.
  23. Pike, L.R., Singleton, D.S., Buffa, F., Abramczyk, O., Phadwal, K., Li, J.L., Simon, A.K., Murray, J.T. and Harris, A.L. (2013): Transcriptional upregulation of ULK1 by ATF4 contributes to cancer cell survival. Biochemical Journal, Jan 15; 449(2): 389-400. doi: 10.1042/BJ20120972.
  24. Chen,Y., Mu, X., Wang, S., Zhao, L., Wu Y., *Li, J.L. and Li, M. (2013): WAP four-disulfide core domain protein 2 mediates the proliferation of human ovarian cancer cells through the regulation of growth- and apoptosis-associated genes. Oncology Reports, Jan; 29(1): 288-296. doi: 10.3892/or.2012.2114. (*corresponding author).
  25. Favaro, E., Bensaad, K., Chong, M.G., Tennant, D.A., Ferguson, D.J., Snell, C., Steers, G., Turley, H., Li, J.L. et al. (2012): Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence incancer cells. Cell Metabolism, Dec 5; 16(6): 751-764. doi: 10.1016/j.cmet.2012.10.017.
  26. Jones, D.T., Lechertier, T., Mitter, R., Herbert, J.M., Bicknell, R., Jones, J.L., Li,J.L., Buffa, F., Harris, A.L. and Hodivala-Dilke, K. (2012): Gene expression analysis in human breast cancer associated blood vessels. PLoS ONE, 7(10): e44294. doi: 10.1371/journal.pone.0044294.
  27. McIntyre, A., Patiar, S., Wigfield, S., Li, J.L., Ledaki, I., Turley,H., Leek, R., Snell, C., Gatter, K.C., Sly, W.S., Vaughan-Jones, R.D., Swietach, P. and Harris, A.L. (2012): Carbonic anhydrase IX promotes tumour growth and necrosis in vivo and inhibition enhances anti-VEGF therapy. Clinical Cancer Research, Jun 1; 18(11):3100-3111. doi: 10.1158/1078-0432.CCR-11-1877.
  28. *Li, J.L., Sanson, R.C., Oon, C.E., Turley, H., Leek, R., Sheldon, H., Bridges, E., Shi, W., Snell, C., Bowden, E.T., Wu, H., Chowdhury, P.S., Russell, A.J., Montgomery, C.P., Poulsom, R. and Harris, A.L. (2011): DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Research, Sep 15; 71(18): 6073-6083. doi: 10.1158/0008-5472.CAN-11-1704. (*corresponding author).
  29. Wang, S., Huang, X., Li, Y., Lao, H., Zhang, Y., Dong, H., Xu, W., *Li, J.L. and Li, M. (2011): RN181 suppresses hepatocellular carcinoma growth by inhibition of the ERK/MAPK pathway. Hepatology, Jun; 53(6): 1932-1942. doi: 10.1002/hep.24291. (*corresponding author).
  30. Coutts, A.S., Pires, I.M., Weston, L., Buffa, F.M., Milani, M., Li, J.L., Harris, A.L., Hammond, E.M. and La Thangue, N.B. (2011): Hypoxia-driven cell motility reflects the interplay between JMY and HIF-1α. Oncogene, Dec 1; 30(48): 4835-4842. doi: 10.1038/onc.2011.
  31. Sheldon, H., Heikamp, E., Turley, T., Dragovic, R., Thomas, P., Oon, C.E., Leek. R., Edelmann, M., Kessler, B., Sainson, R.C., Sargent, I., Li, J.L. and Harris, A.L. (2010): New mechanism for Notch signaling to endothelium at a distance by Delta-like 4 incorporation into exosomes. Blood, Sep 30; 116(13): 2385-2394. doi: 10.1182/blood-2009-08-239228.
  32. Chen, L., Zeng,X., Wang, J., Briggs, S.S., O’Neill, E., Li, J.L. et al. (2010): Roles of tetrahydrobiopterin in promoting tumor angiogenesis. The American Journal of Pathology, Nov; 177(5):2671-2680. 
  33. *Li, J.L., Jubb, A.M. and Harris, A.L. (2010): Targeting DLL4 in tumors shows preclinical activity but potentially significant toxicity. Future Oncology, Jul; 6(7): 1099-1103. (*corresponding author).
  34. Favaro, E., Ramachandran, A., McCormick, R., Gee, H., Blancher, C., Crosby, M., Devlin, C., Blick, C., Buffa, F., Li, J.L., Vojnovic, B., deNeves, R.P., Glazer, P., Iborra, F., Ivan, M., Ragoussis, J. and Harris, A.L. (2010): MicroRNA-210 regulates mitochondrial free radical response to hypoxia and Krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU. PLoS ONE, Apr 26; 5(4): e10345.
  35. Biswas, S., Troy, H., Leek, R., Chung, Y.L., Li, J.L., Raval, R., Turley, H., Gatter, K., Pezzella, F., Griffiths, J.R., Stubbs, M. and Harris, A.L. (2010): Effects of HIF-1a and HIF-2a on growth and metabolism of clear-cell renal cell carcinoma 786-0 xenografts. Journal of Oncology, 2010; 2010: 757908.
  36. Jubb, A.M., Soilleux, E.J., Turley, H., Steers, G., Parker, A., Low, I., Li, J.L., Leek, R., Noguera-Troise, I., Pezzella, F., Gatter, K.C., Thurston, G. and Harris, A.L. (2010): Prognostic impact of Delta-like ligand 4 (Dll4) and inflammatory markers in breast cancer. The American Journal of Pathology, Apr; 176(4): 2019-2028.
  37. Pires, I.M., Bencokova, Z., Milani, M., Folkes, L.K., Li, J.L., Stratford, M.R., Harris, A.L. and Hammond, E.M. (2010): Chronic hypoxia leads to replisome disassembly and an inhibition of the DNA damage response. Cancer Research, Feb 1; 70(3): 925-935.
  38. Hao, J.M., Chen, J.Z., Sui, H.M., Si-Ma, H.Q., Li, G.Q., Liu, C., Li,J.L., Ding, Y.Q. and Li, J.M. (2010): A five-gene signature as a predictor of metastasis and survival in colorectal cancer. The Journal of Pathology, Mar; 220(4): 475-489.
  39. Jubb, A.M., Turley, H., Moeller, H.C., Steers, G., Han, C., Li, J.L., Leek, R., Singh, B., Mortensen, N.J., Noguera-Troise, I., Pezzella, F., Gatter, K.C., Fox, S.B., Thurston, G. and Harris, A.L. (2009): Expression of delta-like ligand4 (Dll4) and markers of hypoxia in colon cancer. British Journal of Cancer, 101(10): 1749-1757.
  40. Yang, J., Ledaki, I., Turley, H., Gatter, K.C., Montero, J-C., Li, J.L., and Harris, A.L. (2009): Role of hypoxic inducible factors in epigenetic regulation via histone demethylases. Annals of the New York Academy of Sciences, Oct; 1177:185-197.
  41. Martinez, J.C., Müller, M.M., Turley, H., Steers, G., Choteau, L., Li, J.L., Sainson, R., Harris, A.L., Pezzella, F. and Gatter, K.C. (2009): Nuclear and membrane expression of the angiogenesis regulator Delta-like ligand 4 (DLL4) in normal and malignant human tissues. Histopathology, Apr; 54(5):598-606.
  42. *Li, J.L. (2009): DNA replication in the human malaria parasite and potential for novel drug development. In “Molecular Themes in DNA Replication” Edited by Lynne S Cox, published by the Royal Society of Chemistry, ISBN: 978-0-85404-164-0,Chapter 13, 363-392. (*corresponding author).
  43. *Li, J.L. and Harris, A.L. (2009): Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications. Frontiers in Bioscience, Jan 1; 14: 3094-3110. (*corresponding author).
  44. Harrington, L.S., Sainson, R.C., Williams, C.K., Taylor, J.M., Shi, W., Li, J.L. and Harris, AL. (2008): Regulation of multiple angiogenic pathways by DLL4 andNotch in human umbilical vein endothelial cells. Microvascular Research, Mar; 75(2): 144-154.
  45. *Li, J.L., Sainson, R.C., Shi, W., Leek, R., Harrington, L.S., Preusser, M., Biswas, S., Turley, H., Heikamp, E., Hainfellner, J.A. and Harris, A.L. (2007): Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Research, Dec 1; 67(23): 11244-11253. (*corresponding author).
  46. *Li, J.L. and Harris, A.L. (2007): The potential of new tumor endothelium-specific markers for the development of anti-vascular therapy. Cancer Cell, Jun; 11(6):478-482. (*corresponding author).
  47. Patel, N.S., Dobbie, M. S., Rochester, M., Steers, G., Poulsom, R., Cranston, D.W., Li, J.L. and Harris, A.L. (2006):Up-regulation of endothelial Delta-like 4 expression correlates with vessel maturation in bladder cancer.  Clinical Cancer Research, Aug 15; 12(16): 4836-4844.
  48. Williams, C.K., Li, J.L., Murga, M., Harris, A.L. and Tosato,G. (2006): Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood, Feb 1; 107(3): 931-939.
  49. *Li, J.L. and Harris, A.L. (2006): Notch signalingfrom tumor cells: a new mechanism of angiogenesis. Cancer Cell, Jul; 8(1): 1-4. (*corresponding author).
  50. Patel, N.S., *Li, J.L., Generali, D., Poulsom, R., Cranston, D.W. and Harris, A.L. (2005): Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Research, Oct 1; 65(19): 8690-8697. (*corresponding author).
  51. Raval, R.R., Lau, K.W., Tran, M.G., Sowter, H.M., Mandriota, S.J., Li, J.L., Pugh, C.W., Maxwell, P.H., Harris, A.L. and Ratcliffe, P.J. (2005): Contrasting properties of hypoxia-inducible factor HIF-1 and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Molecular and Cellular Biology, Jul; 25(13): 5675-5686.
  52. Jiao, R., Bachrati, C.Z., Pedrazzi, G., Kuster, P., Petkovic, M., Li, J.L., Egli, D., Hickson, I.D. and Stagljar, I. (2004): Physical and functional interaction between the Bloom’s syndrome gene product and the largest subunit of chromatin assembly factor 1. Molecular and Cellular Biology, Jun; 24(11): 4710-4719.
  53. Braybrooke, J.P.,  *Li, J.L., Wu, L., Caple, F., Benson, F.E. and Hickson, I.D. (2003): Functional interaction between the Bloom's syndrome helicase and the RAD51 paralog, RAD51L3 (RAD51D). The Journal of Biological Chemistry, Nov 28; 278(48): 48357-48366. (*co-first author).
  54. *Li, J.L. and Cox, L.S. (2003): Characterisation of a sexual stage-specific gene encoding ORC1 homologue in the human malaria parasite Plasmodium falciparum. Parasitology International, Mar; 52(1): 41-52. (*corresponding author).
  55. *Li, J.L., Warren, A.V. and Cox, L.S. (2002): Identification of a second proliferating cell nuclear antigen in the human malarial pathogen Plasmodium falciparum. International Journal for Parasitology, Dec 19; 32(14): 1683-1692. (*corresponding author).
  56. Yang, Q., Zhang, R., Wang, X., Spillare, E.A., Linke, S.P., Subramanian, D., Griffith, J.D., Li, J.L., Hickson, I.D., Shen, J.C., Loeb, L.A., Mazur, S.J., Appella, E., Brosh, R.M. Jr, Karmakar, P., Bohr, V.A. and Harris,C.C. (2002): The processing of Holliday junctions by BLM and WRN helicases is regulated by p53. The Journal of Biological Chemistry, Aug 30; 277(35): 31980-31987.
  57. Li, J.L., Brosh, R.M., Bohr, V.A., Neidle, S. and Hickson, I.D. (2001): Inhibition of the Bloom's and Werner's syndrome helicases by G-quadruplex interacting ligands. Biochemistry, Dec 18; 40(50): 15194-15202.
  58. *Li, J.L. and Cox, L.S. (2001): Identification of an MCM4 homologue expressed specifically in the sexual stage of Plasmodium falciparum. International Journal for Parasitology, Sep; 31(11): 1246-1252. (*corresponding author).
  59. *Li, J.L., Targett, G.A.T. and Baker, D.A. (2001): Primary structure and sexual stage-specific expression of a LAMMER protein kinase of Plasmodium falciparum. International Journal for Parasitology, Apr; 31(4): 387-392. (*corresponding author).
  60. Hickson, I.D., Davies, S.L., Li, J.L., Levitt N.C., Mohaghegh, P., North, P.S. and Wu, L. (2001): Role of the Bloom's syndrome helicase in maintenance of genome stability. Biochemical Society Transactions, May; 29(2):201-204.
  61. Karow, J.K., Constantinou, S., Li, J.L., West, S.C. and Hickson, I.D. (2000): The Bloom’s syndrome gene product promotes branch migration of Holliday junctions. Proc Natl Acad Sci U S A., Jun 6; 97(12):6504-6508.
  62. Brosh, R.M., Li, J.L., Kenny, M.K., Karow, J.K., Cooper, M.P., Kureekattil, R.P., Hickson, I.D. and Bohr, V.A. (2000): Replication protein A physically interacts with the Bloom syndrome protein and stimulates its helicase activity. The Journal of Biological Chemistry, Aug 4; 275(31): 23500-23508.
  63. Li, G.D., Li, J.L., Mugthin, M. and Ward, S.A. (2000): Molecular cloning of a gene encoding a 20S proteasome b-subunit from Plasmodium falciparumInternational Journal for Parasitology, May; 30(6): 729-733.
  64. *Li, J.L. and Cox, L.S. (2000)Isolation and characterisation of a cAMP-dependent protein kinase catalytic subunit from Plasmodium falciparum. Molecular and Biochemical Parasitology, Jul; 109(2): 157-163. (*corresponding author).
  65. *Li, J.L., Baker,D.A. and Cox, L.S. (2000): Sexual stage-specific expression of a third calcium-dependent protein kinase of Plasmodium falciparum. Biochimica et Biophysica Acta, Apr 25; 1491(1-3): 341-349. (*corresponding author).          
  66. Carucci, D.J., Witney, A.A., Muhia, D.K., Warhurst, D.C., Schaap, P., Meima, M., Li, J.L., Taylor, M.C., Kelly, J.M. and Baker, D.A. (2000): Guanylyl cyclase activity associated with putative bifunctional integral membrane proteins in Plasmodium falciparum. The Journal of Biological Chemistry, Jul 21; 275(29): 22147-22156.
  67. Baker, D.A. and *Li, J.L. (1999): A family of PP2 phosphatases in Plasmodium falciparum and parasitic protozoa. Parasitology Today, Mar; 15(3): 124-. (*corresponding author).
  68. *Li, J.L. and Baker, D.A. (1998): A putative protein serine/threonine phosphatase from Plasmodium falciparum contains a large N-terminal extension and five unique inserts in the catalytic domain. Molecular and Biochemical Parasitology, Sep15; 95(2): 287-295. (*corresponding author).
  69. *Li, J.L. and Baker,D.A. (1997): Protein phosphatase b, a putative type-2A protein phosphatase from the human malaria parasite Plasmodium falciparumEuropean Journal of Biochemistry, Oct 1; 249(1): 98-106. (*corresponding author).
  70. *Li, J.L., Robson, K.J.H., Chen, J.L., Targett, G.A.T. and Baker, D.A. (1996): Pfmrk, a MO15-related kinase from Plasmodium falciparum: cloning, sequence, stage-specific expression and chromosome localization. European Journal of Biochemistry, Nov 1; 242(2): 805-813. (*corresponding author).
  71. *Li, J.L., Li, Y.J., Chao, S., Ouyang, M.H. and Peng, Y.B. (1993): Serum-free medium for long-term growth, freezing, cloning and fusion of myelomas and hybridomas. In Vitro Cellular and Developmental Biology, Feb; 29A(2): 87-88. (*corresponding author).
  72. *Li, J.L., Chen, J.L., Ouyang, M.H., Chao, S., Peng, Y.B., Lin, L.X.M., Chang, W.S. and Li, Y.J. (1991): Immunization strategies for the production of rat monoclonal anti-idiotype antibodies. Journal of Immunological Methods, Aug 28; 142(1): 15-20. (*corresponding author).
  73. *Li, J.L., Li, Y.J.,Chao,S., Lin, L.X.M., Ouyang, M.H., Peng, Y.B. and Chang, W.S. (1991): Cholesterol requirement for growth of IR983F and P3X63-Ag8-U1 myeloma cells in serum-free medium. Cytobios, 68(272): 15-22. (*corresponding author).

GenBank Submission (accession number)

Li JL et al.:  U73195; U88869; U89025; AF056205; AF056206; AF065397; AF069296; AF071408; AF071409; AF083323; AF093702; AF095948; AF104915; AF106064; AF126257; AF126719; AF139108; AF139827; AF170073;  AF251283;  AF251284;  AF284763;  AF356553; AF373219.

Links

Ji-Liang Li - Google Scholar Citations

https://www.researchgate.net/profile/Ji-Liang_Li